Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab

Linda Myrin-Westesson; Anna Olsson

doi:10.2478/jhp-2025-0011

Abstract

Abstract Introduction

Emicizumab is a humanised, bispecific monoclonal antibody that bridges activated factor (F) IX and FX; it is approved for treatment of people with haemophilia A (PwHA) of all ages, with or without FVIII inhibitors. Qualitative experiences of PwHA switching to non-factor treatments, such as emicizumab, are needed to facilitate shared decision-making (SDM).

Aim

This study aimed to describe experiences of switching from FVIII prophylaxis to emicizumab among PwHA.

Methods

Participants with severe haemophilia A without FVIII inhibitors from the Swedish cohort of the HemiNorth 2 study (MO42245; EudraCT# 2020-003256-32) were subject to qualitative interviews in 2023, which were analysed through content analysis.

Results

Overall, nine participants were interviewed. The analysis revealed three categories: ‘Adapting to a new reality’, ‘A feeling of normality’ and ‘Shattered expectations’. Participants reported that switching from FVIII prophylaxis to emicizumab fostered a feeling of normality, with the disease taking less time and space in their daily lives. The participants also described increased confidence in physical activity, and a newfound hope for the future treatment of haemophilia. However, not all expectations were met, as the disease persisted and still affected daily life. Some participants also reported a lack of information about emicizumab from a patient perspective.

Conclusion

The findings convey a sense of normality among PwHA switching to emicizumab, stemming from a reduced disease and treatment burden. The results highlight the gaps in knowledge among PwHA, which can help inform SDM practice and manage expectations when switching to a non-factor treatment.

Article

View Full Article

References

1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26(Suppl 6): 1–158. doi: https://doi.org/10.1111/hae.14046.
2. Davari M, Gharibnaseri Z, Ravanbod R, Sadeghi A. Health status and quality of life in patients with severe hemophilia A: A cross-sectional survey. Hematol Rep 2019; 11(2): 7894. doi: https://doi.org/10.4081/hr.2019.7894.
3. O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes 2018; 16(1): 84. doi: https://doi.org/10.1186/s12955-018-0908-9.
4. Poenaru D, Sandulescu MI, Cinteza D. Intraarticular management of chronic haemophilic arthropathy. Biomed Rep 2023; 19(3): 59. doi: https://doi.org/10.3892/br.2023.1641.
5. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost 2021; 19(9): 2112–2121. doi: https://doi.org/10.1111/jth.15444.
6. Witkop M, Guelcher C, Forsyth A, et al. Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18–30 years) with hemophilia. Am J Hematol 2015; 90(S2): S3–S10. doi: https://doi.org/10.1002/ajh.24220.
7. Wiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 2019; 25(3): 433–440. doi: https://doi.org/10.1111/hae.13754.
8. Trindade GC, Viggiano LGL, Brant ER, et al. Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires. Hematol Transfus Cell Ther 2019; 41(4): 335–341. doi: https://doi.org/10.1016/j.htct.2019.03.010.
9. Mahlangu J, Oldenburg J, Callaghan MU, et al. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia 2019; 25(3): 382–391. doi: https://doi.org/10.1111/hae.13731.
10. Oldenburg J, Tran H, Peyvandi F, et al. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia 2021; 27(3): 398–407. doi: https://doi.org/10.1111/hae.14270.
11. von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388(4): 310–318. doi: https://doi.org/10.1056/NEJMoa2209226.
12. Hermans C, Reding MT, Astermark J, Klamroth R, Mancuso ME. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician’s perspective. Crit Rev Oncol Hematol 2022; 174: 103678. doi: https://doi.org/10.1016/j.critrevonc.2022.103678.
13. Blair HA. Emicizumab: a review in haemophilia A. Drugs 2019; 79(15): 1697–1707. doi: https://doi.org/10.1007/s40265-019-01200-2.
14. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117(7): 1348–1357. doi: https://doi.org/10.1160/TH17-01-0030.
15. Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25(1): 33–44. doi: https://doi.org/10.1111/hae.13618.
16. Young G, Liesner R, Chang T, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–2138. doi: https://doi.org/10.1182/blood.2019001869.
17. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–822. doi: https://doi.org/10.1056/NEJMoa1803550.
18. Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25(6): 979–987. doi: https://doi.org/10.1111/hae.13848.
19. Yang R, Wang S, Wang X, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemostast 2022; 6(2): e12670. doi: https://doi.org/10.1002/rth2.12670.
20. Négrier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol 2023; 10(3): e168–e177. doi: https://doi.org/10.1016/S2352-3026(22)00377-5.
21. Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood 2024; 143(14): 1355–1364. doi: https://doi.org/10.1182/blood.2023021832.
22. European Medicines Agency. HEMLIBRA^® solution for injection: Emicizumab. [Initial EU approval: 2018.] 2023. Available from https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf (accessed November 2024).
23. Skinner MW, Negrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–865. doi: https://doi.org/10.1111/hae.14363.
24. Hassan AS, Sherief LM, Hamdy M, Salamah A, El-Agamy OA. Physical activity limitations in children with severe haemophilia A. Does emicizumab make a difference? J Pak Med Assoc 2023; 73(Suppl 4): S31–S33. doi: https://doi.org/10.47391/JPMA.EGY-S4-10.
25. Oldenburg J, Pipe SW, Mancuso ME, et al. Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP. Current Med Res Opin 2023; 39(2): 219–225. doi: https://doi.org/10.1080/03007995.2022.2116173.
26. Thornburg CD, Coffin D. How clinicians and persons with hemophilia may approach shared decision-making. Expert Rev Hematol 2024; 17(6): 193–196. doi: https://doi.org/10.1080/17474086.2024.2353761.
27. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 2004; 24(2): 105–112. doi: https://doi.org/10.1016/j.nedt.2003.10.001.
28. Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nursing 2008; 62(1): 107–115. doi: https://doi.org/10.1111/j.1365-2648.2007.04569.x.
29. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 2014; 89(9): 1245–1251. doi: https://doi.org/10.1097/ACM.0000000000000388.
30. Björkqvist J, Astermark J, Holme PA, et al. Non-interventional study on health-related quality of life, physical activity and bleeds in severe non-inhibitor hemophilia A patients with a bleeding phenotype on FVIII prophylaxis in the Nordics. Res Pract Thromb Haemost 2024; 8: 363–364.
31. Weller SC, Vickers B, Bernard HR, et al. Open-ended interview questions and saturation. PLoS One 2018; 13(6): e0198606. doi: https://doi.org/10.1371/journal.pone.0198606.
32. Oka G, Roussel-Robert V, Levivien C, Lopez I, Pieragostini R. Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy. Haemophilia 2023; 29(3): 709–715. doi: https://doi.org/10.1111/hae.14755.
33. Kempton C, Trask P, Parnes A, et al. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia 2021; 27(2): 221–228. doi: https://doi.org/10.1111/hae.14222.
34. Fletcher S, Jenner K, Holland M, Khair K. The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me. Health Expect 2022; 25(1): 443–454. doi: https://doi.org/10.1111/hex.13404.
35. Oladapo AO, Lu M, Walsh S, O’Hara J, Kauf TL. Inhibitor clinical burden of disease: a comparative analysis of the CHESS data. Orphanet J Rare Dis 2018; 13(1): 198. doi: https://doi.org/10.1186/s13023-018-0929-9.
36. Biasoli C, Baldacci E, Coppola A, et al. Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project. Blood Transfus 2022; 20(1): 66–77. doi: https://doi.org/10.2450/2021.0138-21.
37. Kiialainen A, Niggli M, Kempton CL, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia 2022; 28(6): 1033–1043. doi: https://doi.org/10.1111/hae.14642.
38. DiBenedetti D, Neme D, Pan-Petesch B, et al. Patient experience with efanesoctocog Alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Therapeutics 2024; S0149-2918(24): 272–278. doi: https://doi.org/10.1016/j.clinthera.2024.09.010.
39. Lattimore SU, Hofstetter MT. Patient and family engagement during treatment change to emicizumab at a hemophilia treatment center. Blood 2019; 134(Supplement 1): :5796. doi: https://doi.org/10.1182/blood-2019-131030.
40. Valentino LA BV, Negrier C, O’Mahony B, Bias V, Sannie T, Skinner MW. Personalising haemophilia management with shared decision making. J Haem Pract. 2021; 8(1): 69–79. doi: https://doi.org/10.17225/jhp00178.
41. van Balen EC, Wesselo ML, Baker BL, et al. Patient perspectives on novel treatments in haemophilia: A qualitative study. Patient 2020; 13(2): 201–210. doi: https://doi.org/10.1007/s40271-019-00395-6.
42. Martinoli C, Della Casa Alberighi O, Di Minno G, et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109(6): 1170–1179. doi: https://doi.org/10.1160/TH12-11-0874.

PDF Download

Download PDF

Open in full-page viewer

Authors

Linda Myrin-Westesson

linda.myrin-westesson@gu.se

Region Västra Götaland, Sahlgrenska University Hospital, Department of Medicine, Gothenburg, Sweden
Anna Olsson

Region Västra Götaland, Sahlgrenska University Hospital, Department of Medicine, Gothenburg, Sweden